Nkarta to Participate at Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical firm focused on engineered NK cell therapies for cancer, announced its participation in several upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical firm focused on engineered NK cell therapies for cancer, announced its participation in several upcoming investor conferences. Notable events include the Cowen 5th Annual IO Next Summit on November 15, 2021, at 11:15 a.m. ET, the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 2:00 p.m. ET, and the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 4:20 p.m. ET. Each session will be webcast live and available for replay on Nkarta's website.
Details
News Market Reaction – NKTX
The recorded move for NKTX in the trading session of this news was -2.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:
Cowen 5th Annual IO Next Summit
November 15, 2021
11:15 a.m. ET - fireside chat presentation
Stifel 2021 Virtual Healthcare Conference
November 17, 2021
2:00 p.m. ET – fireside chat presentation
Evercore ISI 4th Annual HealthCONx Conference
December 1, 2021
4:20 p.m. ET – fireside chat presentation
A simultaneous webcast of the presentations will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.